XML 33 R42.htm IDEA: XBRL DOCUMENT v2.4.0.8
Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)
In Millions, unless otherwise specified
1 Months Ended 12 Months Ended
May 31, 2009
Dec. 31, 2013
Segment
Dec. 31, 2009
Summary Of Significant Accounting Policies [Line Items]      
Payment for original sublicense agreement $ 12.0    
Hatch-Waxman Extension   5 years  
Upfront payment received under Fanapt sublicense agreement from Novartis     $ 200.0
Number of business segment   1